All In MedTech

Device Trial Radar · NCT02042066

Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension

Efficacy and Safety of Low Intensity- Extracorporeal Shockwave Therapy in Drug Resistant Hypertension

Last checked: Nov 20, 2026Latest source record: Jan 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

10

Planned (sponsor's estimate)

Start

Jan 2015

Primary completion

Jan 2016

Sponsor

Lead sponsor
MedispecNot on our public-company list
Sponsor type
Industry
Collaborators
Hadassah Medical Organization
First posted
Jan 22, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Low intensity shockwaves have been proven in animal and human studies to increase tissue perfusion, promote angiogenesis and tissue regeneration and improve neural function. The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with resistant hypertension.

Conditions

  • Hypertension, Resistant to Conventional Therapy

Interventions

  • Omnispec model VascuspecDevice

    Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ambulatory Blood Pressure Monitoring (ABPM)Time frame: 6 Months
  2. Ambulatory Blood Pressure Monitoring (ABPM)Time frame: 3 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Medical Organization

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.